A detailed history of Danske Bank A/S transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Danske Bank A/S holds 150 shares of HRMY stock, worth $5,104. This represents 0.0% of its overall portfolio holdings.

Number of Shares
150
Holding current value
$5,104
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 19, 2025

BUY
$26.76 - $38.05 $448,470 - $637,679
16,759 Added 11172.67%
16,909 $466,000
Q3 2025

Nov 13, 2025

BUY
$26.76 - $38.05 $4,014 - $5,707
150 New
150 $4.13 Million
Q2 2025

Dec 18, 2025

SELL
$27.94 - $35.91 $565,226 - $726,459
-20,230 Reduced 43.33%
26,462 $836,000
Q1 2025

Dec 18, 2025

BUY
$32.18 - $40.46 $958,416 - $1.21 Million
29,783 Added 176.14%
46,692 $1.55 Million

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.01B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Danske Bank A/S Portfolio

Follow Danske Bank A/S and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

News

Stay updated on Danske Bank A/S with notifications on news.